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Key questions
What is already known about this subject?
 ► Angina with no obstructive coronary artery disease 
(ANOCA) is a common syndrome with unmet clinical 
needs.
 ► A significant proportion of these patients may suffer 
from microvascular and vasospastic angina.
 ► Diagnosis in this patients may be challending, are 
there are uncertain associations between the re-
sults of reference invasive diagnostic tests and the 
non-invasive ischaemia test results.
What does this study add?
 ► Novel CMR methods for measuring myocardial 
blood flow have not been validated in patients with 
ANOCA and underlying microvascular and vaso-
spastic angina.
 ► The CorCMR substudy represents the largest co-
hort of ANOCA patients with paired multiparametric 
CMR and comprehensive invasive coronary vascu-
lar function tests. CorCMR will provide information 
on the diagnostic value of quantitative pixel-wise 
mapping of myocardial perfusion in patients with 
ANOCA.
How might this impact on clinical practice?
 ► In contrast to the reference standard invasive tests 
of coronary artery function, non-invasive imaging is 
safer and more acceptable to patients.
 ► The CorCMR sub-study presents a unique opportu-
nity to assess and validate the diagnostic accuracy 
of fully-quantitative stress perfusion CMR in patients 
with ANOCA and comprehensive invasive coronary 
artery function testing.
AbstrAct
Introduction Angina with no obstructive coronary artery 
disease (ANOCA) is a common syndrome with unmet 
clinical needs. Microvascular and vasospastic angina are 
relevant but may not be diagnosed without measuring 
coronary vascular function. The relationship between 
cardiovascular magnetic resonance (CMR)-derived 
myocardial blood flow (MBF) and reference invasive 
coronary function tests is uncertain. We hypothesise 
that multiparametric CMR assessment will be clinically 
useful in the ANOCA diagnostic pathway.
Methods/analysis The Stratified Medical Therapy 
Using Invasive Coronary Function Testing In Angina 
(CorMicA) trial is a prospective, blinded, randomised, 
sham-controlled study comparing two management 
approaches in patients with ANOCA. We aim to recruit 
consecutive patients with stable angina undergoing 
elective invasive coronary angiography. Eligible patients 
with ANOCA (n=150) will be randomised to invasive 
coronary artery function-guided diagnosis and treatment 
(intervention group) or not (control group). Based on 
these test results, patients will be stratified into disease 
endotypes: microvascular angina, vasospastic angina, 
mixed microvascular/vasospastic angina, obstructive 
epicardial coronary artery disease and non-cardiac 
chest pain. After randomisation in CorMicA, subjects will 
be invited to participate in the Coronary Microvascular 
Angina Cardiac Magnetic Resonance Imaging (CorCMR) 
substudy. Patients will undergo multiparametric CMR 
and have assessments of MBF (using a novel pixel-wise 
fully quantitative method), left ventricular function and 
mass, and tissue characterisation (T1 mapping and 
late gadolinium enhancement imaging). Abnormalities 
of myocardial perfusion and associations between 
MBF and invasive coronary artery function tests will be 
assessed. The CorCMR substudy represents the largest 
cohort of ANOCA patients with paired multiparametric 
CMR and comprehensive invasive coronary vascular 
function tests.
Ethics/dissemination The CorMicA trial and CorCMR 
substudy have UK REC approval (ref.16/WS/0192).
Trial registration number NCT03193294.
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InTroduCTIon
Angina and stable coronary syndromes (SCSs)
Ischaemic heart disease is the leading cause of mortality 
standardised by age and sex.1 In clinical practice, the 
diagnostic management of patients with angina pectoris 
focuses on the detection of obstructive epicardial coro-
nary artery disease (CAD).2 In this stenosis-centred 
concept of myocardial ischaemia, angina is synonymous 
with obstructive CAD.3 There are well established treat-
ment options for patients with epicardial CAD, namely 
optimal medical therapy and myocardial revascularisa-
tion by either percutaneous coronary intervention or 
coronary artery bypass grafting.3 However, the paradigm 
of angina pectoris resulting from obstructive epicardial 
CAD fails to account for the approximately one-third 
of patients who suffer from angina in whom obstructive 
CAD is excluded.4
Patients with angina and no obstructive coronary artery 
disease (ANOCA) present a diagnostic conundrum.5 
The management of these patients is varied, and most 
patients fail to have a diagnosis made for the cause of 
their symptoms, receive no further diagnostic work-up, 
and have no therapeutic intervention. The underlying 
aetiology of chest pain symptoms and a ‘negative’ coro-
nary angiogram is heterogeneous. However, a significant 
number of patients may have a disorder of coronary 
vascular function due to abnormal microvascular resis-
tance or vasodilator capacity (coronary microvascular 
dysfunction (CMD)) or abnormal endothelial function 
(vasospastic disease).
The underlying pathogenesis in patients with ANOCA 
is unclear, as specific disease endotypes are not routinely 
tested for. CMD may result from coronary structural 
abnormalities, whereby decreased capillary luminal size 
and number result in increased microvascular resistance 
to myocardial blood flow (MBF) and reduced vasodila-
tory capacity.6 Functional abnormalities of the coronary 
epicardial vessels and microvasculature may result in 
either abnormal vasoconstriction or impaired vasodilata-
tion, and these abnormalities may be secondary to either 
endothelium-dependent or endothelium-independent 
mechanisms.7
Abnormalities of coronary vascular function portend 
a worse prognosis in patients with both obstructive 
epicardial CAD and ANOCA.8–12 Therapeutic interven-
tions are lacking in patients with ANOCA, and historical 
therapeutic studies have been performed in heteroge-
neous patient cohorts due to a lack of diagnostic tests 
to appropriately define endotypes of disease.13–15 There 
is a missing link between the use of diagnostic tests of 
coronary artery function, therapeutic agents with proven 
efficacy and health outcomes of patients with angina 
secondary to disorders of coronary vascular function. 
The term stable coronary
syndrome (SCS) has been proposed to increase physi-
cian awareness of these conditions.5 CMD and vaso-
spastic disease may result in ANOCA and myocardial 
ischaemia, and are recognised as a condition of unmet 
clinical need.16 The Coronary Vasomotion Disorders 
International Study Group (COVADIS) working group 
have proposed diagnostic criteria for disease endotypes 
in patients with ANOCA.17 COVADIS recommend a 
comprehensive testing strategy incorporating tests of 
coronary pressure, flow, resistance and endothelial func-
tion, in addition to the assessment of objective evidence 
of myocardial ischaemia.17
diagnostic testing in patients with AnoCA
Diagnosis of coronary microvascular and vasomotor 
dysfunction is challenging due to the heterogeneity of 
underlying disease mechanisms, the potentially patchy 
distribution of disease throughout the myocardium, and 
limited spatial resolution of existing diagnostic tests.18 19 
There is no available in vivo technique for imaging the 
coronary microcirculation, and anatomical tests are 
fundamentally limited by their spatial resolution and the 
small size of the coronary microvasculature. Therefore, 
the diagnosis of microvascular angina and vasospastic 
angina is predominantly made with functional tests.
There is no accepted guideline-directed diagnostic 
algorithm for coronary vascular dysfunction in routine 
clinical practice.17 20 Invasive coronary angiography 
combined with adjunctive tests of coronary artery func-
tion represents the reference diagnostic approach for 
disorders of coronary vascular function. In contrast, 
non-invasive imaging involves less discomfort for 
patients, is safer than invasive procedures and is gener-
ally less expensive and more widely available. Recent 
developments with cardiovascular magnetic resonance 
(CMR) imaging now enable measurement of MBF with 
high spatial and temporal resolution.21 In addition, CMR 
permits the reference standard non-invasive assessment 
of left ventricular (LV) function and myocardial tissue 
characterisation.22
non-invasive ischaemia testing in AnoCA
The available non-invasive ischaemia tests were all validated 
for the detection of obstructive epicardial CAD. There 
has been a low yield of inducible myocardial ischaemia in 
ANOCA patients with traditional non-invasive ischaemia 
tests (e.g. exercise ECG testing, myocardial perfusion scin-
tigraphy and stress echocardiography).23 However, non-in-
vasive methods (namely stress perfusion positron emission 
tomography (PET) and CMR which image earlier in the 
ischaemic cascade and have greater spatial resolution) 
may provide new insights into the burden of myocardial 
ischaemia in patients with ANOCA. PET is the most studied 
modality for the assessment of myocardial perfusion and is 
considered to provide the reference standard assessment 
of MBF, but in real-world clinical practice, availability is 
limited due to cost. Conversely, CMR is more widely avail-
able and use is increasing.24 25
Coronary microvascular disease may be revealed by a 
deficit in MBF during stress CMR. The spatial distribution 
of this abnormality typically involves the subendocardium, 
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Figure 1 CorCMR substudy flow diagram. ANOCA, 
angina with no obstructive coronary artery disease; CMR, 
cardiovascular magnetic resonance; CorCMR, Coronary 
Microvascular Angina Cardiac MRI; CorMicA, coronary 
microvascular angina.
which is the location of the microvascular plexus.26 In 
contrast, vasospastic angina occurs due to spontaneous 
spasm of the epicardial and microvascular vasculature. 
Vasospastic angina may not be detected by conventional 
stress testing that routinely use adenosine (an endothe-
lial-independent vasodilator). The available data are 
conflicting on the role of perfusion CMR in patients with 
ANOCA.26–28 In contrast to qualitative analysis, semiquan-
titative perfusion methods have been investigated, and 
reduced myocardial perfusion reserve index (MPRi) has 
been found in patients with ANOCA.29 The incremental 
diagnostic value of fully quantitative perfusion CMR in 
patients with ANOCA is unknown.
Associations between invasive and non-invasive diagnostic 
tests in patients with AnoCA
There are uncertain associations between the results of 
invasive diagnostic tests and the non-invasive ischaemia 
test results in patients with ANOCA. There is no accepted 
objective diagnostic threshold for the diagnosis of coro-
nary vascular dysfunction (either abnormal myocardial 
flow or microvascular resistance), with either PET or 
perfusion CMR. Recent studies have investigated the 
relationships between invasive tests of coronary artery 
function and semiquantitative perfusion CMR anal-
ysis.30 31 Importantly, these patients have not undergone 
comprehensive coronary vascular function testing and in 
general moderate correlations were demonstrated (MPRi 
and index of microcirculatory resistance (IMR): r=−0.67; 
MPRi and coronary flow reserve (CFR): r=0.41).30
The Stratified Medical Therapy using Invasive Coronary 
Function Testing In Angina (CorMicA) trial
The Stratified Medical Therapy Using Invasive Coronary 
Function Testing In Angina (CorMicA) clinical trial is 
a proof-of-concept, prospective, blinded, randomised, 
sham-controlled study comparing two management 
approaches to the clinical problem of patients with 
ANOCA.32 CorMicA tests the hypothesis that stratified 
medicine guided by invasive coronary artery function 
testing (interventional diagnostic procedure (IDP)) 
in patients with ANOCA will facilitate diagnosis of the 
underlying disease endotype, direct therapeutic inter-
ventions aligned to the endotype and result in improved 
angina and well-being.32 Patients undergoing elective 
invasive coronary angiography for investigation of angina 
at two UK centres will be screened. Eligible patients with 
ANOCA (n=150) will be immediately randomised 1:1 
to either coronary vascular function-guided diagnosis 
and treatment (intervention group/IDP disclosed) or 
not (control group/IDP sham procedure, results not 
disclosed) (figure 1).
The IDP consists of coronary artery function testing 
using a dual pressure-sensitive and temperature-sensi-
tive guidewire and adenosine followed by intracoronary 
acetylcholine provocation testing. Assessment of micro-
vascular resistance (IMR), microvascular vasodilatory 
capacity (resistance reserve ratio (RRR)), epicardial 
and microvascular vasodilatory capacity (CFR), endo-
thelial function (acetylcholine provocation testing) 
and epicardial CAD (fractional flow reserve (FFR)) will 
be performed. Following these invasive tests of coro-
nary artery function, patients will be classified into the 
following ANOCA disease endotypes (table 1): (1) micro-
vascular angina; (2) vasospastic angina; (3) mixed micro-
vascular angina and vasospastic angina; (4) obstructive 
epicardial CAD; and (5) non-cardiac chest pain. The 
disease endotypes are aligned with the COVADIS working 
group definitions.17
Patients in the control group will receive standard care 
based on the interpretation of the invasive coronary angio-
gram alone. Patients in the intervention group will have 
care based on the disease endotypes disclosed by invasive 
tests of artery function, and pharmacotherapy linked to 
the underlying disease endotype will be commenced.32 In 
each case, the diagnosis (endotype) will be assessed by 
the attending cardiologist before and after the coronary 
angiogram. In the intervention group, the diagnosis is 
re-evaluated after disclosure of the coronary function test 
results at the end of the invasive procedure. The primary 
outcome is the mean difference in the within-subject 
change in Seattle Angina Questionnaire score between 
the groups at 6 months from baseline. A prespecified 
substudy of the CorMicA trial investigated the frequency 
of peripheral microvascular dysfunction in patients with 
ANOCA.33
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Table 1 Definitions of ANOCA disease endotypes
Disease endotype Mechanism Invasive diagnostic test
Microvascular angina ↑ Microvascular resistance IMR ≥25
↓ Coronary vasorelaxation CFR <2.0
↓ Microvascular vasodilator capacity RRR <2.0
Microvascular spasm ACh testing: angina, ischaemic ST segment deviation, epicardial coronary 
vasoconstriction <90%.
Vasospastic angina Epicardial spasm ACh testing: angina, ischaemic ST segment deviation, >90% epicardial coronary 
vasoconstriction.
Mixed microvascular and vasospastic 
angina
CMD and epicardial vasospasm Epicardial vasospasm and either ↑ microvascular resistance, ↓ coronary 
vasorelaxation or ↓ microvascular vasodilator capacity.
Obstructive epicardial
CAD
Epicardial stenosis >50% lesion by diameter stenosis in epicardial artery >2.5 mm or FFR ≤0.80.
Non-cardiac pain Nil Exclusion of epicardial (FFR >0.8), microvascular (CFR >2.0, IMR <25, RRR >2.0) 
vasospasm (normal ACh response).
ACh, acetylcholine; ANOCA, angina with no obstructive coronary artery disease; CAD, coronary artery disease; CFR, coronary flow 
reserve; CMD, coronary microvascular dysfunction; FFR, fractional flow reserve; IMR, index of microcirculatory resistance; RRR, relative 
resistance ratio.
Coronary Microvascular Angina Cardiac Magnetic resonance 
Imaging (CorCMr) sub-study
Novel CMR methods for measuring MBF have not been 
validated in patients with ANOCA and underlying micro-
vascular and vasospastic angina. The CorCMR substudy 
of the CorMicA clinical trial presents a unique oppor-
tunity to assess and validate the diagnostic accuracy of 
fully quantitative stress perfusion CMR in patients with 
ANOCA and comprehensive invasive coronary artery 
function testing.
Hypothesis
We hypothesise that abnormal myocardial perfusion, 
as revealed by a novel fully quantitative pixel-wise CMR 
perfusion sequence, will be prevalent in a contemporary 
UK cohort of patients presenting with ANOCA and that 
multiparametric CMR imaging will be clinically useful in 
the diagnostic pathway of patients with ANOCA.
Aims
We aim to assess the diagnostic validity of quantita-
tive stress perfusion CMR in patients with ANOCA and 
specific disease endotypes of coronary vascular dysfunc-
tion. Our specific aims are to assess:
1. The proportion of ANOCA patients with abnormal 
myocardial perfusion. There is no accepted thresh-
old for abnormal MPR. Thresholds for reduced CFR 
of 1.5–2.6 have been described,however <2.0 is com-
monly used.10 34–38 We will therefore assess the con-
cordance of patient classification using this MPR <2.0 
threshold against endotypes determined by invasive 
testing. Second, we will assess the MPR value with the 
highest area under the curve (AUC) for classification 
of microvascular angina based on the invasive tests 
(reference classification). Third, we will assess the 
proportion of ANOCA endotypes with other abnor-
mal perfusion metrics (reduced stress MBF, abnormal 
endocardial:epicardial MBF ratio and abnormal myo-
cardial dyssynchrony index).39
2. The diagnostic accuracy of the perfusion CMR metrics 
for abnormal invasive tests of coronary artery function 
(IMR >25, CFR <2.0 and RRR <2.0) and the associa-
tions between specific disease endotypes and myocar-
dial perfusion in patients with ANOCA. We also aim 
to assess the correlation between abnormal CMR-de-
rived perfusion and invasive tests of coronary artery 
function, of qualitative versus quantitative perfusion 
methods.
3. The proportion of patients with ANOCA and abnor-
mal myocardial tissue characterisation derived from 
CMR (as revealed by T1 parametric mapping and late 
gadolinium enhancement (LGE) imaging) and its as-
sociation with abnormal myocardial perfusion.
4. The associations between baseline patient characteris-
tics and abnormal myocardial perfusion.
5. The proportion of patients with a change in diagno-
sis based on quantitative CMR findings, as compared 
with the initial diagnosis by the attending cardiologist 
based on the coronary angiogram.
METHodS And AnAlySIS
Study design
Prespecified substudy of the CorMicA stratified medical 
therapy clinical trial.
Setting
Patients referred from 14 acute hospitals to two large 
regional UK hospitals (Golden Jubilee National Hospital 
and Hairmyres Hospital) providing invasive care to all 
patients in the West of Scotland (population 2.5 million). 
All CMR studies will be performed at the Golden Jubilee 
National Hospital.
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Figure 2 CorCMR multiparametric imaging protocol. CorCMR, Coronary Microvascular Angina Cardiac MRI.
Participants
Consecutive outpatients undergoing clinically indicated 
elective diagnostic angiography for investigation of 
suspected angina will be screened and invited to partic-
ipate in the CorMicA trial. Informed consent is obtained 
before the invasive coronary angiogram. A minimum of 
400 consecutive patients undergoing elective invasive 
coronary angiography is expected to be screened to enrol 
150 subjects with ANOCA within 24 months. Consenting 
patients who are not randomised (e.g. demonstrated to 
have obstructive epicardial disease or logistical reasons) 
will enter a registry. Only patients randomised in the 
CorMicA trial (both in the intervention and control 
groups) are eligible to participate in the CorCMR 
substudy.
Inclusion criteria
Age ≥18 years, a clinically indicated plan for invasive coro-
nary angiography and symptoms of angina (according to 
the Rose angina questionnaire).
Exclusion criteria
A non-coronary indication for invasive angiography (e.g. 
valvular heart disease and cardiomyopathy), obstructive 
epicardial CAD disease evident in a main coronary artery 
(diameter >2.5 mm) (defined as diameter stenosis >50% 
or FFR ≤0.80) and contraindication to contrast-enhanced 
CMR (glomerular filtration rate <30 mL/min, CMR 
unsafe devices).
CMr protocol and analysis
Patients will undergo perfusion CMR within 42 days of the 
CorMicA trial invasive coronary artery function testing. 
CMR studies will be performed at 1.5 Tesla (Siemens 
MAGNETOM Avanto, Erlangen, Germany), and patients 
will undergo a standardised CMR protocol. All patients 
will be asked to abstain from caffeine-containing bever-
ages or foodstuffs for 24 hours and vasoactive medications 
for 48 hours prior to the CMR examination. All scan 
acquisitions will be spatially coregistered. All CMR anal-
yses will be performed by analysts blinded to the invasive 
coronary artery function test results. The standardised 
CMR protocol is demonstrated in figure 2.
Myocardial perfusion
Stress and rest first-pass perfusion imaging will be 
performed using an echo planar imaging dual-sequence 
investigational perfusion method, which consists of a 
low resolution arterial input function image, followed by 
three short axis (base, mid and apex) myocardial images 
during each R–R interval.40–42 Vasodilator stress will be 
achieved with adenosine infusion 140–210 µg/kg/min 
for 3 min. Resting first-pass perfusion will be performed 
at least 10 min later.
The raw stress and rest perfusion images will be quali-
tatively assessed for inducible or fixed perfusion defects. 
Perfusion defects will be reported on a segmental basis 
according to the American Heart Association 16-segment 
model.43 Dark banding artefact will be adjudicated based 
on standardised criteria.22
Pixel-wise perfusion maps will be generated and anal-
ysed to derive fully quantitative MBF estimates on a pixel-
wise basis in mL/g/min of myocardium. The pixel-wise 
perfusion method uses a series of automated postpro-
cessing steps on the raw Digital Imaging and Communi-
cations in Medicine images to generate fully quantitative 
pixel maps.21 The pixel-wise time-signal intensity curves 
will then be quantified using model-constrained Fermi 
deconvolution.44–46
The myocardial perfusion dyssynchrony index is a novel 
perfusion metric that assesses temporal differences in the 
distribution of gadolinium-based contrast media myocar-
dial wash-in. This index has the potential to increase the 
diagnostic sensitivity and specificity of perfusion CMR 
for abnormalities of myocardial perfusion in patients 
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box 2 Continued
Associations of abnormal perfusion with baseline 
characteristics
 ► Sex, age and traditional CAD risk factors
 ► CAD risk scores (JBS3 and ASSIGN)
 ► Gensini score of epicardial plaque burden
Associations of abnormal perfusion with invasive coronary 
artery function testing data
 ► Association of myocardial perfusion with IMR, CFR, RRR and endo-
thelial function testing (continuous and binary)
 ► Subset of patients with multivessel invasive coronary artery func-
tion measurements
 ► Association with clinical diagnosis (ANOCA disease endotype)
Associations of abnormal perfusion with baseline CMr 
data
 ► LV volumes and mass
 ► Myocardial strain
 ► Native T1 relaxation time and ECV
 ► Presence of LGE
diagnostic accuracy
 ► Diagnostic accuracy of quantitative perfusion CMR to detect abnor-
mal IMR, CFR, RRR and endothelial dysfunction
AHA, American Heart Association; ANOCA, angina with no obstructive 
coronary artery disease; BP, blood pressure; CFR, coronary flow reserve; CAD, 
coronary artery disease; CO, cardiac output; CorCMR, Coronary Microvascular 
Angina Cardiac MRI; EF, ejection fraction; EDV, end-diastolic volume; ESV, 
end-systolic volume; ECV, extracellular volume; HR, heart rate; IMR, index 
of microcirculatory resistance; LV, left ventricular; LGE, late gadolinium 
enhancement; MBF, myocardial blood flow; MPR, myocardial perfusion reserve; 
RRR, relative resistance ratio, 
box 2. CorCMR substudy secondary outcomes and analyses
lV volumes, function and mass
 ► LV EF
 ► LVEDV
 ► LV EDV index
 ► LV ESV
 ► LV ESV index
 ► LV mass
 ► LV mass index
 ► LV CO
 ► LV CO index
Atrial area
 ► Left atrial area (cm2)
 ► Left atria dilated (Y/N)
 ► Right atrial area (cm2)
 ► Right atria dilated (Y/N)
Qualitative perfusion analysis
 ► Abnormal perfusion (Y/N)
 ► Number of abnormal segments (n)
 ► Transmurality of perfusion defects (%)
 ► Pattern (epicardial, microvascular, mixed and equivocal)
Quantitative perfusion analysis
 ► Global MPR <2.0 (Y/N)
 ► Segmental/AHA MPR
 ► Global stress and rest MBF
 ► Segmental/AHA territory stress and rest MBF
 ► Global stress endocardial:epicardial MPR ratio
 ► Segmental/AHA territory endocardial:epicardial MPR ratio
Perfusion dyssynchrony analysis
 ► Myocardial perfusion dyssynchrony index (variance and coefficient 
of variation of the time to maximum signal intensity upslope and 
time to peak myocardial signal intensity enhancement)
Adenosine vasodilator stress response
 ► Splenic switch-off (Y/N)
 ► HR and BPchange
 ► Rate-pressure product at rest and stress
late gadolinium enhancement imaging
 ► Abnormal LGE (Y/N).
 ► Number of affected AHA segments (n)
 ► Pattern of abnormal LGE (ischaemic and non-ischaemic)
 ► Myocardial infarct scar burden (transmurality, infarct mass, infarct 
mass as percentage LV mass)
native T1 and ECV mapping
 ► Native T1 (global and midseptal values)
 ► ECV (global and midseptal values)
Myocardial strain
 ► Feature-tracking and DENSE (two methods)
 ► Longitudinal strain (global and by AHA segment)
 ► Circumferential strain (global and by AHA segment)
 ► Radial strain (global and by AHA segment)
Incidental findings
 ► Present (Y/N)
 ► Clinically significant (Y/N)
Continued
with ANOCA.39 Global perfusion dyssynchrony indices 
will be measured as both variance [s2] and percentage 
coefficient of variation of time to maximum signal inten-
sity upslope and time to peak myocardial signal intensity 
enhancement.
Extracardiac anatomy and LV volumes, function and mass
Fast gradient echo images in the axial, coronal and 
sagittal planes will be qualitatively assessed for extra 
cardiac anatomy and pathology and clinically relevant 
incidental findings.
Steady-state free procession ‘cine’ imaging using a 
trueFISP sequence (multislice single-shot breath-hold 
true fast imaging) will be performed in the three long-
axis and short-axis planes for assessment of LV volumes, 
function and mass.
Myocardial tissue characterisation
Native T1 mapping will be performed using a modified 
look-locker inversion recovery investigational proto-
type sequence. Images will be obtained in three short-
axis images (base, mid and apex). T1 mapping will be 
performed pre- and post-gadolinium contrast to assess 
the myocardial native T1 relaxation time and estimate 
the myocardial extracellular volume (ECV) in both the 
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mid-septum and globally.47 For the calculation of ECV, 
blood haematocrit will be measured at baseline on enrol-
ment into the CorMicA trial. ECV mapping analysis will 
be performed offline using proprietary software.
LGE imaging will be performed using a segmented 
phase-sensitive inversion recovery turbo fast low-angle 
shot imaging sequence.48 Images will be obtained in the 
three long-axis planes and short-axis images covering the 
entire LV myocardium. The pattern and burden of hype-
renhancement will be qualitatively and quantitatively 
assessed.
Primary and secondary outcomes
Primary outcome
Abnormal myocardial perfusion reserve (global MPR 
<2.0).
Secondary outcomes
A summary of the secondary outcomes is shown in Box 1.
Statistical analyses
The CorMicA trial has a comprehensive statistical anal-
ysis plan that governs all statistical aspects of the study 
authored by the trial statistician. The statistical analysis 
plan includes the prespecified CorCMR substudy that is 
designed to assess for associations between CMR meas-
ures and invasive measures and endotypes (reference 
dataset). Continuous outcomes will be analysed using 
linear regression with adjustment for baseline levels 
where available. Where continuous data are clearly not 
normally distributed, standard transformations will be 
applied to achieve approximate normality prior to anal-
ysis. Appropriate alternative regression methods will be 
applied to other types of data (eg, logistic regression for 
binary outcomes).
Sample size calculation
The primary outcome is the proportion of patients with an 
MPR<2.0. The proportion of patients with microvascular 
angina defined by invasive endotyping will be assessed. 
We will further assess the MPR ratio with the highest AUC 
for microvascular angina classified invasively.
Considering the correlation between CFR measured 
invasively and MPR measured non-invasively within 
the common territory of a major epicardial coronary 
artery, then a sample size of 110 subjects would enable 
a minimum clinically significant correlation of 0.3 to 
be detected with 90% power at a 5% significance level. 
If only 60 subjects have available data, then 80% power 
would be available to detect a correlation of 0.37 at the 
5% level.
dISCuSSIon
The British Heart Foundation CorMicA trial will assess 
a routine stratified medicine strategy in a large cohort 
of prospectively enrolled patients with ANOCA. The 
prespecified CorCMR substudy will involve comprehen-
sive invasive tests of coronary artery function paired with 
multiparametric perfusion CMR studies. The analysis will 
provide information on the diagnostic value of quantita-
tive pixel-wise mapping of myocardial perfusion in this 
population.
Contemporary guidelines recommend functional 
testing, including with CMR, to assess for myocardial 
ischaemia in patients in whom multidetector CT coro-
nary angiography has shown CAD of uncertain functional 
significance or is non-diagnostic.49 Increasingly, patients 
are referred to the catheter laboratory based on the 
results of anatomical imaging using CT coronary angi-
ography or with no prior tests based on symptoms and 
a high likelihood of CAD.49 50 The CorCMR substudy in 
CorMicA aims to inform this gap.
The CorCMR substudy will be performed on a 
1.5 Tesla MRI scanner. In comparison, 3.0 Tesla 
imaging permits improved signal-to-noise ratio and 
provides higher in-plane spatial resolution perfusion 
imaging.51 52 However, CMR imaging in the NHS is most 
widely performed at 1.5 Tesla, hence the results from 
CorCMR are clinically relevant and transferable.
literature review
Patients with confirmed microvascular or vasospastic 
angina have a precise diagnosis of the underlying disease 
endotype, and pharmacotherapy may be commenced 
as appropriate. Conversely, patients with normal inva-
sive coronary artery function tests may have antianginal 
therapy appropriately discontinued, and alternative 
causes of chest pain investigated. In comparison with 
invasive tests of coronary artery function, non-invasive 
CMR imaging may be more attractive to patients, but at 
present, the role of CMR in the diagnostic work-up of 
patients is uncertain. CorCMR will provide data on the 
role of CMR in the diagnosis of patients with ANOCA. 
Traditional non-invasive ischaemia testing in patients with 
ANOCA has provided mixed results. Panza et al23 inves-
tigated the yield of non-invasive ischaemia testing in 70 
patients with ANOCA. Patients underwent exercise ECG 
testing, radionuclide angiography, myocardial perfusion 
scintigraphy and dobutamine stress echocardiography. 
Abnormal test results were detected in 31%, 16%, 18% 
and 0% respectively, with no concordance between the 
test results. This led to the conclusion that patients with 
ANOCA did not have inducible myocardial ischaemia as 
a cause for their symptoms. However, there is evidence 
that perfusion CMR may detect abnormalities of MBF in 
patients with ANOCA. Panting et al26 first described the 
use of adenosine stress perfusion CMR in patients with 
ANOCA. Twenty patients with syndrome X and 10 control 
subjects were included, and subendocardial hypoper-
fusion was demonstrated in patients with syndrome 
X using a semiquantitative perfusion metric. A subset 
of 118 women with ANOCA enrolled in the National 
Heart, Lung and Blood Institute-sponsored multicentre 
Women’s Ischemic Syndrome Evaluation (WISE) study 
underwent stress perfusion CMR and invasive microvas-
cular function testing with Doppler wire-derived CFR and 
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endothelial function testing with intracoronary acetyl-
choline.29 Stress perfusion CMR was also performed in 21 
asymptomatic control subjects. Reduced global MPRi was 
found in patients with ANOCA compared with controls 
(1.79 vs 2.23, p<0.0001), and a lower MPRi was predic-
tive of ≥1 abnormal invasive coronary vascular function 
metric (OR=0.78, p<0.0001). An MPRi threshold of 1.84 
predicted an abnormal invasive coronary function metric 
with sensitivity of 73% and specificity of 74%. Qualita-
tive analysis of the perfusion studies found no signifi-
cant differences between the study and control groups 
(summed segments with abnormal perfusion 6.66 vs. 
4.45, p=0.09), suggesting that quantitative perfusion anal-
yses may have greater sensitivity for abnormal perfusion 
in patients with ANOCA.
CorCMR will inform the nascent evidence on the 
presence and magnitude of associations between inva-
sive and non-invasive assessments of coronary vascular 
function. Liu et al compared semiquantitative perfu-
sion CMR against IMR measurement in 50 patients with 
ANOCA and 20 age-matched healthy control subjects.30 
In a ROC analysis, an MPRi threshold of 1.4 was optimal 
for the detection of myocardium with inducible isch-
aemia in patients with obstructive epicardial CAD (FFR 
≤0.8) and in patients with ANOCA. Similarly, Williams 
et al31 performed semiquantitative perfusion CMR and 
measured thermodilution and Doppler flow wire-de-
rived metrics of microvascular resistance (IMR and 
hyperaemic microvascular resistance (hMR), respec-
tively) in a heterogeneous cohort of 54 patients (44 with 
acute myocardial infarction and 10 with stable angina). 
Microvascular function testing was performed in unob-
structed epicardial coronary arteries (FFR >0.8). MPRi 
correlated with hMR (r=0.58, p<0.001) but not IMR 
(r=−0.27, p=0.15). These comparisons are between a 
non-invasive metric of vasodilatory capacity (MPRi) and 
an invasive metric of microvascular resistance (IMR and 
hMR), which may more specifically reflect fixed struc-
tural changes in the microcirculation (rather than vaso-
dilator capacity).
CMR permits the reference-standard non-inva-
sive assessment of myocardial tissue characterisation. 
CorCMR will provide data on diffuse interstitial fibrosis, 
ECV and myocardial scar. The role of T1 mapping and 
ECV analysis in patients with ANOCA is uncertain. In a 
substudy of the iPOWER natural history study, 54 women 
with ANOCA underwent native T1 mapping and ECV 
analysis, PET-derived MBF measurement, and trans-
thoracic Doppler echocardiography CFR assessment.53 
There was no correlation found between abnormal coro-
nary vascular function as revealed by PET or echocardi-
ography-derived CFR, and myocardial native T1 or ECV. 
Occult myocardial infarction in patients with ANOCA 
may be clinically relevant. In a substudy of the WISE 
cohort, Wei et al54 performed CMR imaging in 340 female 
patients with ANOCA. A total of 26 patients (8%) had 
hyperenhancement on LGE imaging, with 18 patients 
having evidence of occult myocardial infarction (mean 
scar size 5.1 g), and 8 patients had a non-ischaemic 
pattern (mean scar size 8.9 g).
ETHICS And dISSEMInATIon
Progress in the trial will be monitored by the trial anager 
(KB) and sponsor. The study will be subject to internal 
and external audit that is routinely coordinated by the 
sponsor. An annual report will be submitted to the 
Research Ethics Committee on a 12-month basis. The 
flow diagram illustrates conservative estimates of patient 
enrolment and activity on a single site. The study will 
follow Standards for Reporting of Diagnostic Accuracy 
(STARD) (http://www. equator- network. org/ reporting- 
guidelines/ stard/) and Consolidated Standards of 
Reporting Trials (http://www. consort- statement. org/) 
guidelines.
The CorCMR data will be presented at conferences 
and/or published in peer-reviewed journals.
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